52 Week Range
As of on the New York Stock Exchange ∙ Minimum 15 minute delay
3M AVG Volume
52 Week High
52 Week Low
Shares Out (MIL)
Market Cap (MIL)
Dividend (Yield %)
Eli Lilly Says 1 Manufacturing Plant Underwent FDA General Surveillance Inspection Recently
Lilly Announces Agreement To Acquire Disarm Therapeutics
Lilly Statement On NIAID Decision To Pause Enrollment In Activ-3 Clinical Trial
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company's human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists. Its animal health business segment develops, manufactures and markets products for both food animals and companion animals. The Company's human pharmaceutical products include endocrinology products, neuroscience products, oncology products, immunology products and cardiovascular products. The Company's animal health products segment includes products for food animals and products for companion animals. As of December 31, 2018, the Company manufactured and distributed its products through facilities in the United States, Puerto Rico and 14 other countries.
Biotechnology & Drugs
Lilly Corporate Ctr
Drop Code 1094, Lilly Corporate Ctr
David A. Ricks
Chairman of the Board, President, Chief Executive Officer
Joshua L. Smiley
Chief Financial Officer, Senior Vice President
Senior Vice President - Chief Information and Digital Officer
Daniel M. Skovronsky
Senior Vice President, Chief Scientific Officer and President, Lilly Research Laboratories
Melissa Stapleton Barnes
Senior Vice President - Enterprise Risk Management and Chief Ethics and Compliance Officer
Price To Earnings (TTM)
Price To Sales (TTM)
Price To Book (MRQ)
Price To Cash Flow (TTM)
Total Debt To Equity (MRQ)
LT Debt To Equity (MRQ)
Return on Investment (TTM)
Return on Equity (TTM)
Eli Lilly and Co <LLY.N> said late on Tuesday it had hired an independent consultant to review a plant producing its COVID-19 antibody drug after receiving a notice from the U.S. health regulator.
Eli Lilly and Co said late on Tuesday it had hired an independent consultant to review a plant producing its promising COVID-19 drug after receiving notices from the U.S. health regulator.
The dollar rose from a three-week low on Tuesday while U.S. and European shares eased, as news of pauses in trials of a COVID-19 vaccine and a treatment led investors to take stock of recent rallies before chasing further gains.
The U.S. dollar strengthened on Tuesday as investors turned cautious after a Johnson & Johnson COVID-19 study was paused and as hopes dimmed that a fiscal stimulus package could be reached before the presidential election.
* ELI LILLY ANTIBODY TRIAL IS PAUSED BECAUSE OF POTENTIAL SAFETY- NYT REPORTER
The U.S. government expects to be able to provide at no cost more than 1 million doses of antibody treatments for COVID-19 similar to the one President Donald Trump received to treat his illness, according to a top U.S. health official on Friday.
U.S. President Donald Trump said on Friday he is working to get coronavirus antibody drugs developed by Regeneron Pharmaceuticals Inc and Eli Lilly and Co approved quickly and out to hospitals after his own positive coronavirus treatment experience.
Eli Lilly and Co said on Thursday it had entered into an agreement with the Bill & Melinda Gates Foundation for potential supply of its experimental antibody treatments for COVID-19 to low and middle-income countries.
Eli Lilly and Co said on Thursday it had entered into an agreement with the Bill & Melinda Gates Foundation for potential supply of its experimental antibody treatments for COVID-19 to low and middle-income countries. (Reporting by Manas Mishra in Bengaluru; Editing by Shailesh...
Eli Lilly and Co on Wednesday said it applied for U.S. emergency use authorization (EUA) for its experimental COVID-19 antibody treatment and plans to pursue a similar approval for a dual antibody therapy next month after it produced promising data.
Eli Lilly and Co said on Wednesday it had submitted a request to the U.S. Food and Drug Administration for emergency use of its experimental antibody treatment for COVID-19.
Eli Lilly and Co said on Monday its rheumatoid arthritis drug shortened the time to recovery in hospitalized COVID-19 patients when used along with Gilead Sciences Inc's remdesivir.
Eli Lilly and Co said on Monday its rheumatoid arthritis drug Olumiant helped reduce the time taken to recover from COVID-19 in hospitalized patients in a clinical trial.
* NIH'S FAUCI SAYS EXPECTS RESULTS ON EFFECTIVENESS OF ELI LILLY'S ANITBODY TREATMENT IN MILD TO MODERATE COVID-19 FROM ACTIV-2 TRIAL BY OCT. OR EARLY NOV. Further company coverage:
* ELI LILLY AND CO - FULL RESULTS FROM EMPERIAL EXERCISE ABILITY TRIALS PRESENTED
* EMGALITY® DEMONSTRATES REDUCTION IN FREQUENCY, DURATION, AND PAIN SEVERITY IN PATIENTS WITH EPISODIC AND CHRONIC MIGRAINE
Eli Lilly and Co said on Tuesday its treatment, Verzenio, met the trial goal of reducing the risk of early-stage breast cancer returning, sending the company's shares up 11%.
* VERZENIO® (ABEMACICLIB) SIGNIFICANTLY REDUCED THE RISK OF CANCER RETURNING IN PEOPLE WITH HIGH RISK HR+, HER2- EARLY BREAST CANCER
Eli Lilly and Co on Monday said it was launching a study of its rheumatoid arthritis drug baricitinib in patients hospitalized for COVID-19.
U.S. drugmaker Eli Lilly and Co said on Monday it has started a late-stage trial testing its rheumatoid arthritis drug Olumiant in patients hospitalized with COVID-19.
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.